Europe
Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.
In the waning weeks of the fourth quarter of the 2020 fiscal year, AstraZeneca terminated several clinical programs, including some oncology and heart-related studies, as well as one COVID-19 related trial.
Switzerland-based AC Immune SA announced positive interim results from its ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.
Data published in the New England Journal of Medicine shows the once-weekly dose of the glucagon-like peptide-1 (GLP-1) analog significantly reduced weight in patients over the course of 68 weeks.
Belgium-based Galapagos NV and Foster City, California-based Gilead Sciences halted the ISABELA Phase III clinical trial of ziritaxestat in idiopathic pulmonary fibrosis.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
The origins of COVID-19 continue to be debated in the halls of government, and the findings from a recent investigation conducted by the World Health Organization are unlikely to change many minds as the world continues to grapple with the pandemic.
ZYESAMI is intended to block the replication of SARS-CoV-2 in the ATII cell, as well as cytokine synthesis, thereby relieving respiratory distress. It is the only treatment in development that targets these ATII cells, and if approved, would be the first drug on the market for COVID-19 patients critically ill with respiratory failure.
Lonza has been in the process of separating LSI into a standalone unit since 2019.
A final analysis of the Phase III TITAN study shows that Janssen’s ERLEADA®, when added to androgen deprivation therapy, significantly improved overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with placebo.
PRESS RELEASES